Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women, 50 to 80 years of age, both inclusive.~2. Body weight between 40.0 and 99.9 kg, both inclusive, when rounded to the nearest tenth.~3. Postmenopausal~4. Bone mineral density T-score ≤ - 2.5 and ≥ - 4.0 at the lumbar spine (L1 to L4) as assessed by the central imaging vendor based on dual-energy X-ray absorptiometry(DXA) scan.~5. Patients must have at least 3 vertebrae considered evaluable at the lumbar spine (L1 to L4) and at least 1 hip considered evaluable by DXA scan assessed by the central imaging vendor. Patients with unilateral metal in hips that would be allowed for the other side of 1 evaluable hip are included.~6. Patient with albumin-adjusted total serum calcium ≥ 8.5 mg/dL (≥ 2.125 mmol/L) at Screening.~Exclusion Criteria:~1. Patient previously received denosumab, any other monoclonal antibodies, or biologic agents for osteoporosis~2. Patient confirmed or suspected with infection of COVID-19 at Screening, or has contact with COVID-19 patient within 14 days from Screening~3. Patient with history and/or presence of one severe or \> 2 moderate vertebral fractures as determined by central reading of lateral spine X-ray~4. Patient with history and/or presence of hip fracture~5. Patient with history and/or presence of hyperparathyroidism or hypoparathyroidism, irrespective of current controlled or uncontrolled status~6. Patient with current hyperthyroidism (unless well controlled on stable antithyroid therapy)~7. Patient with current hypothyroidism (unless well controlled on stable thyroid replacement therapy)~8. Patient with history and/or presence of bone disease and metabolic disease (except for osteoporosis) that may interfere with the interpretation of the results

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CT-P41 (Type: EXPERIMENTAL): 60 mg/mL single dose administration, Solution for injection in prefilled syringe(PFS)
- US-licensed Prolia (Type: ACTIVE_COMPARATOR): 60 mg/mL single dose administration, Solution for injection in PFS

Based on this trial design, predict the completion outcome and termination type (if applicable).